RESUMO
AIM: Selective serotonin reuptake inhibitors (SSRIs) are used to treat major depressive disorder (MDD) and other psychiatric disorders (e.g., obsessive compulsive disorder, social anxiety disorder, and panic disorder). In MDD treatment, SSRIs do not show remission in approximately 30% of patients, indicating a need for a better treatment option. Forced swimming test (FST) is a behavioral assay to evaluate depression-like behavior and antidepressant efficacy in rodents. In the present study, we evaluated the combination effect of brexpiprazole with SSRIs on FST in mice, in order to investigate their synergistic effect. METHODS: Brexpiprazole (0.003 mg/kg) was intraperitoneally injected to mice 15 min before testing. Escitalopram (10 mg/kg), fluoxetine (75 mg/kg), paroxetine (10 mg/kg), or sertraline (15 mg/kg) were orally administered to mice 60 min before testing. Then, the mice were placed in water and immobility time was measured. Data from animals treated with escitalopram, fluoxetine, paroxetine, and sertraline were pooled as SSRI-treated group data. RESULTS: Combination treatment of brexpiprazole with SSRIs reduced immobility time in FST more than vehicle or each single treatment. A significant interaction effect was confirmed in the combination of brexpiprazole and SSRIs (p = 0.0411). CONCLUSION: Efficacy of adjunctive brexpiprazole has already been demonstrated in clinical trials in MDD patients not adequately responding to antidepressants including escitalopram, fluoxetine, paroxetine, and sertraline. The synergistic antidepressant-like effect of brexpiprazole with SSRIs found in this study supports the already known clinical findings.
Assuntos
Transtorno Depressivo Maior , Inibidores Seletivos de Recaptação de Serotonina , Camundongos , Animais , Fluoxetina/farmacologia , Paroxetina/farmacologia , Paroxetina/uso terapêutico , Sertralina/farmacologia , Natação , Transtorno Depressivo Maior/tratamento farmacológico , Escitalopram , Antidepressivos/uso terapêuticoRESUMO
Otsuka Pharmaceutical Co., Ltd. successfully developed the first dopamine D2 receptor partial agonist approved for schizophrenia, the antipsychotic aripiprazole (Abilify® ). The drug was approved for this indication in the United States in 2002 and has received approval in the United States, Europe, Japan, and many other countries for several indications including schizophrenia, acute mania, adjunctive treatment of major depressive disorder (MDD), irritability associated with autistic disorder, and Tourette's disorder. Otsuka next developed brexpiprazole (Rexulti® ), another D2 receptor partial agonist, which was granted marketing approval in the United States in 2015 as adjunctive therapy in major depressive disorder and for the treatment of schizophrenia. In Japan, brexpiprazole also received approval as a treatment for schizophrenia in 2018. In this review, we describe Otsuka's research history and achievements over the preceding 40 years in the area of antipsychotic drug discovery for dopamine D2 receptor partial agonists.
Assuntos
Transtorno Depressivo Maior , Agonistas de Dopamina , Aripiprazol/uso terapêutico , Transtorno Depressivo Maior/tratamento farmacológico , Dopamina , Agonistas de Dopamina/uso terapêutico , Humanos , Quinolonas , Pesquisa , Tiofenos , Estados UnidosRESUMO
The effects of stable chronic hyponatremia on the central nervous system are largely unknown, clinically, or in experimental animals. The aim of this study was to identify and characterize these effects in rats. Tolvaptan, a vasopressin V(2) receptor antagonist, was used to correct hyponatremia and determine any potential benefits of such treatment in this condition. Stable chronic hyponatremia was induced by combination of the continuous vasopressin V(2) receptor stimulation and liquid food intake. The hyponatremic rats did not exhibit significant changes in general symptoms or neurological functions assessed by modified Irwin's method, or in motor function assessed by the rotarod test. In passive avoidance test, however, rats with moderate and severe hyponatremia had significantly reduced step-through latency, indicating impairment in memory. This reduced step-through latency was improved by the treatment of tolvaptan (0.25-8 mg/kg daily doses), a vasopressin V(2) receptor antagonist. This improvement is associated with normalization of plasma sodium concentrations in hyponatremic rats. In conclusion, these data suggest that chronic hyponatremia may impair memory, and treatments that normalize sodium level, such as vasopressin V(2) receptor antagonists, may be beneficial to patients with hyponatremia.
Assuntos
Antagonistas dos Receptores de Hormônios Antidiuréticos , Benzazepinas/uso terapêutico , Hiponatremia/complicações , Hiponatremia/tratamento farmacológico , Transtornos da Memória/etiologia , Animais , Aprendizagem da Esquiva , Benzazepinas/farmacologia , Água Corporal , Encéfalo , Desamino Arginina Vasopressina/administração & dosagem , Masculino , Memória/efeitos dos fármacos , Atividade Motora , Ratos , Ratos Sprague-Dawley , Tempo de Reação/efeitos dos fármacos , Receptores de Vasopressinas/efeitos dos fármacos , Receptores de Vasopressinas/fisiologia , Sódio/sangue , TolvaptanRESUMO
This study compared the D(2) partial agonists, aripiprazole, (R(+)-terguride; S(-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine [S(-)-3-PPP]; 7-[3-[4-(2,3-dimethylphenyl)piperazinyl]propoxy]-2(1H)-quinolinone [OPC-4392]) and D(2) antagonists (haloperidol, olanzapine, clozapine, risperidone, and quetiapine) on prepulse inhibition (PPI) of the startle response, and the ability to reverse apomorphine-induced deficits in the PPI response. Aripiprazole did not essentially affect PPI in naïve rats but dose-dependently restored apomorphine-induced PPI disruption. R(+)-terguride restored PPI disruption but suppressed PPI significantly in naïve rats, S(-)-3-PPP partially restored whereas OPC-4392 did not restore PPI disruption. Haloperidol and risperidone restored PPI disruption whereas olanzapine and quetiapine partially restored PPI disruption and clozapine had no restorative effect. In conclusion, aripiprazole, unlike other antipsychotic agents, failed to suppress PPI significantly and restored PPI disruption.
Assuntos
Dopaminérgicos/farmacologia , Inibição Neural/efeitos dos fármacos , Piperazinas/farmacologia , Quinolonas/farmacologia , Tempo de Reação/efeitos dos fármacos , Receptores de Dopamina D2/efeitos dos fármacos , Reflexo de Sobressalto/efeitos dos fármacos , Estimulação Acústica , Animais , Antipsicóticos/farmacologia , Apomorfina/farmacologia , Aripiprazol , Condicionamento Clássico/efeitos dos fármacos , Dopaminérgicos/classificação , Interações Medicamentosas , Inibição Psicológica , Ativação do Canal Iônico/efeitos dos fármacos , Masculino , Ratos , Ratos WistarRESUMO
It has recently been suggested that neurogenesis in the dentate gyrus is decreased in schizophrenia and this phenomenon may contribute to the pathogenesis of the disorder. Since repeated administration of psychostimulants such as phencyclidine (PCP), MK-801, and methamphetamine (METH) induces schizophrenia-like behavioral changes in animals, we investigated whether repeated administration of these psychostimulants affects neurogenesis in the dentate gyrus of mice. Newborn cells were labeled by bromodeoxyuridine (BrdU) and detected by immunohistochemistry. Repeated administration of PCP and MK-801, but not METH, resulted in a decrease in the number of BrdU-labeled cells in the dentate gyrus. PCP-induced decrease in the number of BrdU-labeled cells was negated by co-administration of clozapine, but not haloperidol, although repeated antipsychotics treatment by themselves had no effect. Furthermore, co-administration of D-serine and glycine, but not L-serine, inhibited the PCP-induced decrease in the number of BrdU-labeled cells. These results suggest that chronic dysfunction of NMDA receptors causes a decrease in neurogenesis in the dentate gyrus.
Assuntos
Clozapina/administração & dosagem , Antagonistas de Aminoácidos Excitatórios/administração & dosagem , Neurônios/efeitos dos fármacos , Fenciclidina/administração & dosagem , Animais , Giro Denteado/citologia , Giro Denteado/efeitos dos fármacos , Masculino , Camundongos , Camundongos Endogâmicos ICR , Neurônios/citologiaAssuntos
Antipsicóticos/uso terapêutico , Piperazinas/uso terapêutico , Quinolonas/uso terapêutico , Receptores de Dopamina D2/agonistas , Esquizofrenia/tratamento farmacológico , Aripiprazol , Ensaios Clínicos como Assunto , Humanos , Piperazinas/farmacologia , Quinolonas/farmacologia , Receptores de Dopamina D2/fisiologia , Esquizofrenia/fisiopatologiaRESUMO
It is obvious that DA is an important neurotransmitter in vivo. It is involved in a variety of physiological processes such as mental processes, motor function and hormone regulation. In this context, it is quite understandable that a DA D2 receptor antagonist that inhibits the DA D2 receptor regardless of the state of activity of dopaminergic neurotransmission and inhibit the physiological function of DA can have a variety of adverse effects. In contrast to DA D2 antagonists, aripiprazole acts as an antagonist at the DA D2 receptor in the state of excessive dopaminergic neurotransmission, while it acts as an agonist at the DA D2 receptor in the state of low dopaminergic neurotransmission, and thus attempts to bring the state of dopaminergic neurotransmission to normal. This activity of aripiprazole to regulate dopaminergic neurotransmission is physiologically reasonable, and can be regarded as a stabilizing effect, for which aripiprazole is called a dopamine system stabilizer.
Assuntos
Antipsicóticos/farmacologia , Agonistas de Dopamina/farmacologia , Piperazinas/metabolismo , Quinolonas/metabolismo , Receptores de Dopamina D2/agonistas , Animais , Antipsicóticos/uso terapêutico , Aripiprazol , Antagonistas de Dopamina/farmacologia , Antagonistas dos Receptores de Dopamina D2 , Humanos , Estrutura Molecular , Piperazinas/química , Quinolonas/química , Esquizofrenia/tratamento farmacológicoRESUMO
The antipsychotic efficacy of aripiprazole is not generally associated with extrapyramidal symptoms, cardiovascular effects, sedation or elevations in serum prolactin that characterize typical or atypical antipsychotics. The aim of this study was to clarify the mechanism of action of aripiprazole that underlies its favourable clinical profiles. The preclinical efficacy and side-effect profiles of aripiprazole were evaluated using several pharmaco-behavioural test systems in mice and rats, both in vivo and ex vivo, and compared with those of other conventional and atypical antipsychotics. Each of the antipsychotics induced catalepsy and inhibited apomorphine-induced stereotypy. The catalepsy liability ratios for these drugs were 6.5 for aripiprazole, 4.7 for both olanzapine and risperidone. The ptosis liability ratios for aripiprazole, olanzapine and risperidone were 14, 7.2 and 3.3, respectively. Aripiprazole slightly increased DOPA accumulation in the forebrain of reserpinised mice, reduced 5-HTP accumulation at the highest dose and exhibited a weaker inhibition of 5-methoxy-N,N-dimethyl-tryptamine-induced head twitches. Aripiprazole did not inhibit physostigmine- or norepinephrine-induced lethality in rats. In conclusion, aripiprazole shows a favourable preclinical efficacy and side-effect profile compared to a typical antipsychotics. This profile may result from its high affinity partial agonist activity at D2 and 5-HT1A receptors and its antagonism of 5-HT2A receptors.
Assuntos
Antipsicóticos/efeitos adversos , Antipsicóticos/farmacologia , Piperazinas/efeitos adversos , Piperazinas/farmacologia , Quinolonas/efeitos adversos , Quinolonas/farmacologia , Animais , Antipsicóticos/administração & dosagem , Aripiprazol , Benzodiazepinas/efeitos adversos , Benzodiazepinas/farmacologia , Blefaroptose/induzido quimicamente , Catalepsia/induzido quimicamente , Di-Hidroxifenilalanina/biossíntese , Relação Dose-Resposta a Droga , Movimentos da Cabeça/efeitos dos fármacos , Masculino , Metoxidimetiltriptaminas/efeitos adversos , Metoxidimetiltriptaminas/antagonistas & inibidores , Camundongos , Camundongos Endogâmicos ICR , Olanzapina , Piperazinas/administração & dosagem , Prosencéfalo/efeitos dos fármacos , Prosencéfalo/metabolismo , Quinolonas/administração & dosagem , Ratos , Ratos Wistar , Risperidona/administração & dosagem , Risperidona/efeitos adversos , Risperidona/farmacologia , Serotonina/biossíntese , Comportamento Estereotipado/efeitos dos fármacosRESUMO
Catalepsy and changes in striatal and limbic dopamine metabolism were investigated in mice after oral administration of aripiprazole, haloperidol, and risperidone. Catalepsy duration decreased with chronic (21 day) aripiprazole compared with acute (single dose) treatment across a wide dose range, whereas catalepsy duration persisted with chronic haloperidol treatment. At the time of maximal catalepsy, acute aripiprazole did not alter neostriatal dopamine metabolite/dopamine ratios or homovanillic acid (HVA) levels, and produced small increases in dihydroxyphenylacetic acid (DOPAC). Effects were similar in the olfactory tubercle. Dopamine metabolism was essentially unchanged in both regions after chronic aripiprazole. Acute treatments with haloperidol or risperidone elevated DOPAC, HVA, and metabolite/dopamine ratios in both brain areas and these remained elevated with chronic treatment. The subtle effects of aripiprazole on striatal and limbic dopamine metabolism, and the decrease in catalepsy with chronic administration, illustrate fundamental differences in dopamine neurochemical actions and behavioral sequelae of aripiprazole compared to haloperidol or risperidone.